Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase.

Hepatology communications

Zuo ZH, Yu YP, Ren BG, Liu S, Nelson J, Wang Z, Tao J, Pradhan-Sundd T, Bhargava R, Michalopoulos G, Chen Q, Zhang J, Ma D, Pennathur A, Luketich J, Satdarshan Monga P, Nalesnik M, Luo JH.
PMID: 34505419
Hepatol Commun. 2022 Jan;6(1):209-222. doi: 10.1002/hep4.1724. Epub 2021 Sep 10.

Chromosome rearrangement is one of the hallmarks of human malignancies. Gene fusion is one of the consequences of chromosome rearrangements. In this report, we show that gene fusion between solute carrier family 45 member 2 (SLC45A2) and alpha-methylacyl-coenzyme A...

Cite
Zuo ZH, Yu YP, Ren BG, et al. Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase. Hepatol Commun. 2021;6(1):209-222doi: 10.1002/hep4.1724.
Zuo, Z. H., Yu, Y. P., Ren, B. G., Liu, S., Nelson, J., Wang, Z., Tao, J., Pradhan-Sundd, T., Bhargava, R., Michalopoulos, G., Chen, Q., Zhang, J., Ma, D., Pennathur, A., Luketich, J., Satdarshan Monga, P., Nalesnik, M., & Luo, J. H. (2022). Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase. Hepatology communications, 6(1), 209-222. https://doi.org/10.1002/hep4.1724
Zuo, Ze-Hua, et al. "Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase." Hepatology communications vol. 6,1 (2022): 209-222. doi: https://doi.org/10.1002/hep4.1724
Zuo ZH, Yu YP, Ren BG, Liu S, Nelson J, Wang Z, Tao J, Pradhan-Sundd T, Bhargava R, Michalopoulos G, Chen Q, Zhang J, Ma D, Pennathur A, Luketich J, Satdarshan Monga P, Nalesnik M, Luo JH. Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase. Hepatol Commun. 2022 Jan;6(1):209-222. doi: 10.1002/hep4.1724. Epub 2021 Sep 10. PMID: 34505419; PMCID: PMC8710797.
Copy Download .nbib Format: NLM
Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase.

Hepatology communications

Zuo ZH, Yu YP, Ren BG, Liu S, Nelson J, Wang Z, Tao J, Pradhan-Sundd T, Bhargava R, Michalopoulos G, Chen Q, Zhang J, Ma D, Pennathur A, Luketich J, Satdarshan Monga P, Nalesnik M, Luo JH.
PMID: 34505419
Hepatol Commun. 2022 Jan;6(1):209-222. doi: 10.1002/hep4.1724. Epub 2021 Sep 10.

Chromosome rearrangement is one of the hallmarks of human malignancies. Gene fusion is one of the consequences of chromosome rearrangements. In this report, we show that gene fusion between solute carrier family 45 member 2 (SLC45A2) and alpha-methylacyl-coenzyme A...

Cite
Zuo ZH, Yu YP, Ren BG, et al. Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase. Hepatol Commun. 2021;6(1):209-222doi: 10.1002/hep4.1724.
Zuo, Z. H., Yu, Y. P., Ren, B. G., Liu, S., Nelson, J., Wang, Z., Tao, J., Pradhan-Sundd, T., Bhargava, R., Michalopoulos, G., Chen, Q., Zhang, J., Ma, D., Pennathur, A., Luketich, J., Satdarshan Monga, P., Nalesnik, M., & Luo, J. H. (2022). Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase. Hepatology communications, 6(1), 209-222. https://doi.org/10.1002/hep4.1724
Zuo, Ze-Hua, et al. "Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase." Hepatology communications vol. 6,1 (2022): 209-222. doi: https://doi.org/10.1002/hep4.1724
Zuo ZH, Yu YP, Ren BG, Liu S, Nelson J, Wang Z, Tao J, Pradhan-Sundd T, Bhargava R, Michalopoulos G, Chen Q, Zhang J, Ma D, Pennathur A, Luketich J, Satdarshan Monga P, Nalesnik M, Luo JH. Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase. Hepatol Commun. 2022 Jan;6(1):209-222. doi: 10.1002/hep4.1724. Epub 2021 Sep 10. PMID: 34505419.
Copy Download .nbib Format: NLM
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.

Gut

Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD.
PMID: 33849943
Gut. 2021 Apr 13; doi: 10.1136/gutjnl-2020-322595. Epub 2021 Apr 13.

OBJECTIVE: Recent studies have found aristaless-related homeobox gene (ARX)/pancreatic and duodenal homeobox 1 (PDX1), alpha-thalassemia/mental retardation X-linked (ATRX)/death domain-associated protein (DAXX) and alternative lengthening of telomeres (ALT) to be promising prognostic biomarkers for non-functional pancreatic neuroendocrine tumours (NF-PanNETs). However,...

Cite
Hackeng WM, Brosens LAA, Kim JY, et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2021;doi: 10.1136/gutjnl-2020-322595.
Hackeng, W. M., Brosens, L. A. A., Kim, J. Y., O'Sullivan, R., Sung, Y. N., Liu, T. C., Cao, D., Heayn, M., Brosnan-Cashman, J., An, S., Morsink, F. H. M., Heidsma, C. M., Valk, G. D., Vriens, M. R., Nieveen van Dijkum, E., Offerhaus, G. J. A., Dreijerink, K. M. A., Zeh, H., Zureikat, A. H., Hogg, M., Lee, K., Geller, D., Marsh, J. W., Paniccia, A., Ongchin, M., Pingpank, J. F., Bahary, N., Aijazi, M., Brand, R., Chennat, J., Das, R., Fasanella, K. E., Khalid, A., McGrath, K., Sarkaria, S., Singh, H., Slivka, A., Nalesnik, M., Han, X., Nikiforova, M. N., Lawlor, R. T., Mafficini, A., Rusev, B., Corbo, V., Luchini, C., Bersani, S., Pea, A., Cingarlini, S., Landoni, L., Salvia, R., Milione, M., Milella, M., Scarpa, A., Hong, S. M., Heaphy, C. M., & Singhi, A. D. (2021). Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut, . https://doi.org/10.1136/gutjnl-2020-322595
Hackeng, Wenzel M, et al. "Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size." Gut vol. (2021). doi: https://doi.org/10.1136/gutjnl-2020-322595
Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2021 Apr 13; doi: 10.1136/gutjnl-2020-322595. Epub 2021 Apr 13. PMID: 33849943; PMCID: PMC8511349.
Copy Download .nbib Format: NLM
A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients.

Pharmacoepidemiology and drug safety

Kremers HM, Funch DP, Robson RA, Nalesnik MA, Ebrahim S, Cecka MJ, Opelz G, Dreyer NA, Walker AM.
PMID: 15073894
Pharmacoepidemiol Drug Saf. 1999 Dec;8(7):509-18. doi: 10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1.

Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many...

Cite
Kremers HM, Funch DP, Robson RA, et al. A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. Pharmacoepidemiol Drug Saf. 1999;8(7):509-18doi: 10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1.
Kremers, H. M., Funch, D. P., Robson, R. A., Nalesnik, M. A., Ebrahim, S., Cecka, M. J., Opelz, G., Dreyer, N. A., & Walker, A. M. (1999). A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. Pharmacoepidemiology and drug safety, 8(7), 509-18. https://doi.org/10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1
Kremers, H M, et al. "A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients." Pharmacoepidemiology and drug safety vol. 8,7 (1999): 509-18. doi: https://doi.org/10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1
Kremers HM, Funch DP, Robson RA, Nalesnik MA, Ebrahim S, Cecka MJ, Opelz G, Dreyer NA, Walker AM. A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. Pharmacoepidemiol Drug Saf. 1999 Dec;8(7):509-18. doi: 10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1. PMID: 15073894.
Copy Download .nbib Format: NLM
Unheard voices: outcomes of tertiary care for treatment-refractory psychosis.

Psychiatric bulletin (2014)

Sarkar SN, Tracy DK, Fernandez MJ, Nalesnik N, Dhillon G, Onwumere J, Prins AM, Schepman K, Collier T, White TP, Patel A, Gaughran F, Shergill SS.
PMID: 25237502
Psychiatr Bull (2014). 2014 Apr;38(2):71-4. doi: 10.1192/pb.bp.112.042598.

Aims and method In up to a quarter of patients, schizophrenia is resistant to standard treatments. We undertook a naturalistic study of 153 patients treated in the tertiary referral in-patient unit of the National Psychosis Service based at the...

Cite
Sarkar SN, Tracy DK, Fernandez MJ, et al. Unheard voices: outcomes of tertiary care for treatment-refractory psychosis. Psychiatr Bull (2014). 2014;38(2):71-4doi: 10.1192/pb.bp.112.042598.
Sarkar, S. N., Tracy, D. K., Fernandez, M. J., Nalesnik, N., Dhillon, G., Onwumere, J., Prins, A. M., Schepman, K., Collier, T., White, T. P., Patel, A., Gaughran, F., & Shergill, S. S. (2014). Unheard voices: outcomes of tertiary care for treatment-refractory psychosis. Psychiatric bulletin (2014), 38(2), 71-4. https://doi.org/10.1192/pb.bp.112.042598
Sarkar, S Neil, et al. "Unheard voices: outcomes of tertiary care for treatment-refractory psychosis." Psychiatric bulletin (2014) vol. 38,2 (2014): 71-4. doi: https://doi.org/10.1192/pb.bp.112.042598
Sarkar SN, Tracy DK, Fernandez MJ, Nalesnik N, Dhillon G, Onwumere J, Prins AM, Schepman K, Collier T, White TP, Patel A, Gaughran F, Shergill SS. Unheard voices: outcomes of tertiary care for treatment-refractory psychosis. Psychiatr Bull (2014). 2014 Apr;38(2):71-4. doi: 10.1192/pb.bp.112.042598. PMID: 25237502; PMCID: PMC4115394.
Copy Download .nbib Format: NLM
A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Chung RT, King WC, Ghany MG, Lisker-Melman M, Hinerman AS, Khalili M, Sulkowski M, Jain MK, Choi EK, Nalesnik MA, Bhan AK, Cloherty G, Wong DK, Sterling RK.
PMID: 34973459
Clin Gastroenterol Hepatol. 2021 Dec 29; doi: 10.1016/j.cgh.2021.12.038. Epub 2021 Dec 29.

BACKGROUND: The contribution of the novel biomarkers, HBV RNA and HBcrAg, to characterization of HBV-HIV coinfection is unclear. We evaluated the longitudinal dynamics of HBV RNA and HBcrAg and their association with classical HBV serum biomarkers and liver histology...

Cite
Chung RT, King WC, Ghany MG, et al. A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.12.038.
Chung, R. T., King, W. C., Ghany, M. G., Lisker-Melman, M., Hinerman, A. S., Khalili, M., Sulkowski, M., Jain, M. K., Choi, E. K., Nalesnik, M. A., Bhan, A. K., Cloherty, G., Wong, D. K., Sterling, R. K. (2021). A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.12.038
Chung, Raymond T, et al. "A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.12.038
Chung RT, King WC, Ghany MG, Lisker-Melman M, Hinerman AS, Khalili M, Sulkowski M, Jain MK, Choi EK, Nalesnik MA, Bhan AK, Cloherty G, Wong DK, Sterling RK. A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clin Gastroenterol Hepatol. 2021 Dec 29; doi: 10.1016/j.cgh.2021.12.038. Epub 2021 Dec 29. PMID: 34973459.
Copy Download .nbib Format: NLM
A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Chung RT, King WC, Ghany MG, Lisker-Melman M, Hinerman AS, Khalili M, Sulkowski M, Jain MK, Choi EK, Nalesnik MA, Bhan AK, Cloherty G, Wong DK, Sterling RK.
PMID: 34973459
Clin Gastroenterol Hepatol. 2021 Dec 29; doi: 10.1016/j.cgh.2021.12.038. Epub 2021 Dec 29.

BACKGROUND: The contribution of the novel biomarkers, HBV RNA and HBcrAg, to characterization of HBV-HIV coinfection is unclear. We evaluated the longitudinal dynamics of HBV RNA and HBcrAg and their association with classical HBV serum biomarkers and liver histology...

Cite
Chung RT, King WC, Ghany MG, et al. A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.12.038.
Chung, R. T., King, W. C., Ghany, M. G., Lisker-Melman, M., Hinerman, A. S., Khalili, M., Sulkowski, M., Jain, M. K., Choi, E. K., Nalesnik, M. A., Bhan, A. K., Cloherty, G., Wong, D. K., Sterling, R. K. (2021). A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.12.038
Chung, Raymond T, et al. "A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.12.038
Chung RT, King WC, Ghany MG, Lisker-Melman M, Hinerman AS, Khalili M, Sulkowski M, Jain MK, Choi EK, Nalesnik MA, Bhan AK, Cloherty G, Wong DK, Sterling RK. A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clin Gastroenterol Hepatol. 2021 Dec 29; doi: 10.1016/j.cgh.2021.12.038. Epub 2021 Dec 29. PMID: 34973459.
Copy Download .nbib Format: NLM
A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Chung RT, King WC, Ghany MG, Lisker-Melman M, Hinerman AS, Khalili M, Sulkowski M, Jain MK, Choi EK, Nalesnik MA, Bhan AK, Cloherty G, Wong DK, Sterling RK.
PMID: 34973459
Clin Gastroenterol Hepatol. 2021 Dec 29; doi: 10.1016/j.cgh.2021.12.038. Epub 2021 Dec 29.

BACKGROUND: The contribution of the novel biomarkers, HBV RNA and HBcrAg, to characterization of HBV-HIV coinfection is unclear. We evaluated the longitudinal dynamics of HBV RNA and HBcrAg and their association with classical HBV serum biomarkers and liver histology...

Cite
Chung RT, King WC, Ghany MG, et al. A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.12.038.
Chung, R. T., King, W. C., Ghany, M. G., Lisker-Melman, M., Hinerman, A. S., Khalili, M., Sulkowski, M., Jain, M. K., Choi, E. K., Nalesnik, M. A., Bhan, A. K., Cloherty, G., Wong, D. K., Sterling, R. K. (2021). A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.12.038
Chung, Raymond T, et al. "A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.12.038
Chung RT, King WC, Ghany MG, Lisker-Melman M, Hinerman AS, Khalili M, Sulkowski M, Jain MK, Choi EK, Nalesnik MA, Bhan AK, Cloherty G, Wong DK, Sterling RK. A prospective cohort study of novel markers of hepatitis B virus replication in human immunodeficiency virus coinfection. Clin Gastroenterol Hepatol. 2021 Dec 29; doi: 10.1016/j.cgh.2021.12.038. Epub 2021 Dec 29. PMID: 34973459.
Copy Download .nbib Format: NLM
Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients.

Hepatology communications

Liu S, Nalesnik MA, Singhi A, Wood-Trageser MA, Randhawa P, Ren BG, Humar A, Liu P, Yu YP, Tseng GC, Michalopoulos G, Luo JH.
PMID: 34725972
Hepatol Commun. 2021 Nov 01; doi: 10.1002/hep4.1846. Epub 2021 Nov 01.

Hepatocellular carcinoma (HCC) is one of the most lethal human cancers. Liver transplantation has been an effective approach to treat liver cancer. However, significant numbers of patients with HCC experience cancer recurrence, and the selection of suitable candidates for...

Cite
Liu S, Nalesnik MA, Singhi A, et al. Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients. Hepatol Commun. 2021;doi: 10.1002/hep4.1846.
Liu, S., Nalesnik, M. A., Singhi, A., Wood-Trageser, M. A., Randhawa, P., Ren, B. G., Humar, A., Liu, P., Yu, Y. P., Tseng, G. C., Michalopoulos, G., & Luo, J. H. (2021). Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients. Hepatology communications, . https://doi.org/10.1002/hep4.1846
Liu, Silvia, et al. "Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients." Hepatology communications vol. (2021). doi: https://doi.org/10.1002/hep4.1846
Liu S, Nalesnik MA, Singhi A, Wood-Trageser MA, Randhawa P, Ren BG, Humar A, Liu P, Yu YP, Tseng GC, Michalopoulos G, Luo JH. Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients. Hepatol Commun. 2021 Nov 01; doi: 10.1002/hep4.1846. Epub 2021 Nov 01. PMID: 34725972.
Copy Download .nbib Format: NLM
Y Chromosomal Sequences Identified in Gonadal Tissue of Two 45,X Patients with Turner Syndrome.

Endocrine pathology

Kocova M, Witchel SF, Nalesnik M, Lee PA, Dickman PS, MacGillivray MH, Reiter EO, Trucco G, Trucco M.
PMID: 12114813
Endocr Pathol. 1995;6(4):311-322. doi: 10.1007/BF02738731.

We examined excised gonadal tissue obtained from two 45,X patients for evidence of Y chromosomal material. Both patients had features atypical for individuals with Turner syndrome, a large dysgerminoma in patient 1 and clitoromegaly in patient 2. Southern blot...

Cite
Kocova M, Witchel SF, Nalesnik M, et al. Y Chromosomal Sequences Identified in Gonadal Tissue of Two 45,X Patients with Turner Syndrome. Endocr Pathol. 1995;6(4):311-322doi: 10.1007/BF02738731.
Kocova, M., Witchel, S. F., Nalesnik, M., Lee, P. A., Dickman, P. S., MacGillivray, M. H., Reiter, E. O., Trucco, G., & Trucco, M. (1995). Y Chromosomal Sequences Identified in Gonadal Tissue of Two 45,X Patients with Turner Syndrome. Endocrine pathology, 6(4), 311-322. https://doi.org/10.1007/BF02738731
Kocova, Mirjana, et al. "Y Chromosomal Sequences Identified in Gonadal Tissue of Two 45,X Patients with Turner Syndrome." Endocrine pathology vol. 6,4 (1995): 311-322. doi: https://doi.org/10.1007/BF02738731
Kocova M, Witchel SF, Nalesnik M, Lee PA, Dickman PS, MacGillivray MH, Reiter EO, Trucco G, Trucco M. Y Chromosomal Sequences Identified in Gonadal Tissue of Two 45,X Patients with Turner Syndrome. Endocr Pathol. 1995;6(4):311-322. doi: 10.1007/BF02738731. PMID: 12114813.
Copy Download .nbib Format: NLM
Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients.

Clinical transplantation

Nalesnik MA, Locker J, Jaffe R, Reyes J, Cooper M, Fung J, Starzl TE.
PMID: 21151749
Clin Transplant. 1992;6:249-252.

Nearly 6000 solid organ transplants have been performed at the University of Pittsburgh since 1981. Posttransplant lymphoproliferative disorders (PTLD) have occurred in 131 patients, at a frequency of 2.2%. The majority of cases manifest within 6 months following allograft,...

Cite
Nalesnik MA, Locker J, Jaffe R, et al. Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant. 1992;6:249-252
Nalesnik, M. A., Locker, J., Jaffe, R., Reyes, J., Cooper, M., Fung, J., & Starzl, T. E. (1992). Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clinical transplantation, 6249-252.
Nalesnik, Michael A, et al. "Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients." Clinical transplantation vol. 6 (1992): 249-252.
Nalesnik MA, Locker J, Jaffe R, Reyes J, Cooper M, Fung J, Starzl TE. Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant. 1992;6:249-252. PMID: 21151749; PMCID: PMC3000224.
Copy Download .nbib Format: NLM
Comparison of UW with other solutions for liver preservation in dogs.

Clinical transplantation

Todo S, Podesta L, Ueda Y, Imventarza O, Casavilla A, Oks A, Okuda K, Nalesnik M, Venkataramanan R, Starzl TE.
PMID: 21151798
Clin Transplant. 1989 Oct;3(5):253-259.

The efficacy of the University of Wisconsin (UW) solution was compared with conventional Euro-Collins solution, as well as with 3 variants of a silica gel solution developed at the University of Minnesota (UM). Protection of the liver grafts with...

Cite
Todo S, Podesta L, Ueda Y, et al. Comparison of UW with other solutions for liver preservation in dogs. Clin Transplant. 1989;3(5):253-259
Todo, S., Podesta, L., Ueda, Y., Imventarza, O., Casavilla, A., Oks, A., Okuda, K., Nalesnik, M., Venkataramanan, R., & Starzl, T. E. (1989). Comparison of UW with other solutions for liver preservation in dogs. Clinical transplantation, 3(5), 253-259.
Todo, S, et al. "Comparison of UW with other solutions for liver preservation in dogs." Clinical transplantation vol. 3,5 (1989): 253-259.
Todo S, Podesta L, Ueda Y, Imventarza O, Casavilla A, Oks A, Okuda K, Nalesnik M, Venkataramanan R, Starzl TE. Comparison of UW with other solutions for liver preservation in dogs. Clin Transplant. 1989 Oct;3(5):253-259. PMID: 21151798; PMCID: PMC3000168.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries